Tinzaparin has FDA-approved labeling for use in the treatment of acute symptomatic DVT with or without PE when administered in conjunction with warfarin sodium. An advantage of tinzaparin, like all ...
Objective and Design: Tinzaparin and dalteparin are low molecular weight heparins (LMWHs) with different pharmacokinetic and pharmacodynamic profiles that may lead to differences in efficacy and ...